First Trust Advisors’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

First Trust Advisors’s Portfolio KLDO Stock Details KLDO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-55,056	Closed	-$410K	–	2689
2021 Q2	$410K	Sell	55,056 -259	-0.5%	-$1.84K	﹤0.01%	2319
2021 Q1	$448K	Buy	55,315 +17,011	+44%	+$185K	﹤0.01%	2242
2020 Q4	$349K	Sell	38,304 -1,247	-3%	-$10.2K	﹤0.01%	2199
2020 Q3	$438K	Buy	39,551 +28,546	+259%	+$198K	﹤0.01%	2078
2020 Q2	$82K	Buy	11,005 +919	+9%	+$6.16K	﹤0.01%	2336
2020 Q1	$62K	Sell	10,086 -1,954	-16%	-$12.8K	﹤0.01%	2317
2019 Q4	$60K	Sell	12,040 -142	-1%	-$902	﹤0.01%	2373
2019 Q3	$92K	Buy	+12,182	New	+$106K	﹤0.01%	2373

Other funds holding KLDO

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors's KLDO Position: Q3 2021 in Review

First Trust Advisors sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q3 2021, closing a stake of 55,056 shares — an estimated $410K sold.

First Trust Advisors first reported a position in KLDO in Q3 2019 and held it in 8 quarters. The position peaked at $448K in Q1 2021. 71 funds tracked by Wall St. Rank hold KLDO as of Q3 2021.

First Trust Advisors reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
First Trust Advisors sold 55,056 Kaleido Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $410K.
First Trust Advisors first reported a position in Kaleido Biosciences, Inc. Common Stock in Q3 2019 and held it in 8 quarters.
First Trust Advisors's Kaleido Biosciences, Inc. Common Stock position peaked at $448K in Q1 2021.
71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q3 2021.

Based on First Trust Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.